The API Intermediate Market was valued for $139.42 Billion in 2022 and is estimated to reach $284.95 Billion by 2032, exhibiting a CAGR of 7.4% from 2023 to 2032.
Active pharmaceutical ingredients (APIs) are substances or combination of substances used to manufacture a drug product. The raw material used in formulation of active pharmaceutical ingredients is known as API intermediates. API intermediates are material produced in the process of manufacturing of API. There are two types of API intermediates, which Includes chemical intermediates and bulk drug intermediates. A bulk drug intermediate refers to a chemical substance or compound that is produced during the manufacturing process of a pharmaceutical drug. A chemical intermediate, on the other hand, is a compound or substance that is produced during the synthesis or production of various chemicals, Including pharmaceuticals, agrochemicals, dyes, polymers, and other industrial products.
The growth of the API intermediates market is driven by rise in the prevalence of chronic diseases and Increase in number of geriatric populations. APIs and intermediates possess application in high-quality drugs used for the treatment of diseases, such as oncology, cardiology, central nervous system (CNS) and neurology, orthopedic, pulmonology, gastroenterology, nephrology, ophthalmology, and endocrinology. APIs and intermediates can potentially create a more sustainable healthcare system by introducing more innovative products. Thus, rise in number of populations suffering from chronic diseases, such as cardiac diseases, is anticipated to fuel the demand for API intermediates and boosts the market growth. For instance, according to the British Heart Foundation, around 1,139,140 people were suffering from heart and circulatory diseases in the UK in 2022. As per the same source, around 650,681 male and 488,320 female population were suffering from heart and circulatory diseases in the UK in 2022.
Moreover, according to the American Heart Association, 244.1 million people were estimated to be living with ischemic heart disease (IHD) in 2020. As per the same source, IHD was more prevalent in males than in females, 141.0 and 103.1 million people, respectively.
In addition, the American Cancer Society reported that, around 1,918,030 new cases of cancer detected in the U.S. in 2022. Moreover, World Cancer Research Fund International, (WCRFI), reported that around 18.1 million new cancer cases were detected in 2020 globally. Furthermore, rise in number of populations suffering from pulmonary and gastrointestinal disorders is expected to Increase the demand for API intermediates and fuels the growth of the market. The global initiative for chronic obstructive lung disease (GOLD), in 2022, reported that 200 million people had chronic obstructive pulmonary disease (COPD), of which about 3.2 million die each year, making it the third-leading cause of death globally. In addition, as per the same source, asthma is one of the most common non-communicable diseases, globally affecting 262 million people in 2022.
High presence of companies who manufacture API intermediates is anticipated to boost the growth of the market. For instance, Shubham Specialty Products, Akums Drugs & Pharmaceuticals Ltd., Vasoya Industrial Pvt. Lmt., Corey Organics, Icon Pharma Chem, and SLN Pharmachem are some of the key market players who manufacture API intermediates.
However, the high cost associated with the acquisition of biopharmaceutical drugs is a major factor hampering the growth of global API intermediates market. Also, the high cAPItal investment required to produce API intermediates is expected to restrain the market growth.
On the contrary, rise in initiative taken by government of different countries such as India, China, Japan, and others, for development of healthcare infrastructure and Increase in expenditure for development of API intermediates manufacturing units are anticipated to offer remunerative opportunities for the expansion of the market during the forecast period.
The global API intermediates market is segmented into type, application, end user, and region. By type, the market is divided into bulk drug intermediates and chemical intermediates. On the basis of application, the market is divided into analgesics, anti-infective drugs, antidiabetic drugs, cardiovascular drugs, anticancer drugs and others. By end user, the market is segmented into biotech & pharmaceutical companies, CMO and research laboratories. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global API intermediates market Include Anyang General Chemical Co., Ltd., Sandoo Pharmaceuticals, Evonik Industries AG, Shree Ganesh Remedies Limited, Pfizer, Cambrex Corporation, Zeal & Innovation in Medicine, cation pharma, Hikal Ltd., and Espee.
Active pharmaceutical ingredients (APIs) are substances or combination of substances used to manufacture a drug product. The raw material used in formulation of active pharmaceutical ingredients is known as API intermediates. API intermediates are material produced in the process of manufacturing of API. There are two types of API intermediates, which Includes chemical intermediates and bulk drug intermediates. A bulk drug intermediate refers to a chemical substance or compound that is produced during the manufacturing process of a pharmaceutical drug. A chemical intermediate, on the other hand, is a compound or substance that is produced during the synthesis or production of various chemicals, Including pharmaceuticals, agrochemicals, dyes, polymers, and other industrial products.
The growth of the API intermediates market is driven by rise in the prevalence of chronic diseases and Increase in number of geriatric populations. APIs and intermediates possess application in high-quality drugs used for the treatment of diseases, such as oncology, cardiology, central nervous system (CNS) and neurology, orthopedic, pulmonology, gastroenterology, nephrology, ophthalmology, and endocrinology. APIs and intermediates can potentially create a more sustainable healthcare system by introducing more innovative products. Thus, rise in number of populations suffering from chronic diseases, such as cardiac diseases, is anticipated to fuel the demand for API intermediates and boosts the market growth. For instance, according to the British Heart Foundation, around 1,139,140 people were suffering from heart and circulatory diseases in the UK in 2022. As per the same source, around 650,681 male and 488,320 female population were suffering from heart and circulatory diseases in the UK in 2022.
Moreover, according to the American Heart Association, 244.1 million people were estimated to be living with ischemic heart disease (IHD) in 2020. As per the same source, IHD was more prevalent in males than in females, 141.0 and 103.1 million people, respectively.
In addition, the American Cancer Society reported that, around 1,918,030 new cases of cancer detected in the U.S. in 2022. Moreover, World Cancer Research Fund International, (WCRFI), reported that around 18.1 million new cancer cases were detected in 2020 globally. Furthermore, rise in number of populations suffering from pulmonary and gastrointestinal disorders is expected to Increase the demand for API intermediates and fuels the growth of the market. The global initiative for chronic obstructive lung disease (GOLD), in 2022, reported that 200 million people had chronic obstructive pulmonary disease (COPD), of which about 3.2 million die each year, making it the third-leading cause of death globally. In addition, as per the same source, asthma is one of the most common non-communicable diseases, globally affecting 262 million people in 2022.
High presence of companies who manufacture API intermediates is anticipated to boost the growth of the market. For instance, Shubham Specialty Products, Akums Drugs & Pharmaceuticals Ltd., Vasoya Industrial Pvt. Lmt., Corey Organics, Icon Pharma Chem, and SLN Pharmachem are some of the key market players who manufacture API intermediates.
However, the high cost associated with the acquisition of biopharmaceutical drugs is a major factor hampering the growth of global API intermediates market. Also, the high cAPItal investment required to produce API intermediates is expected to restrain the market growth.
On the contrary, rise in initiative taken by government of different countries such as India, China, Japan, and others, for development of healthcare infrastructure and Increase in expenditure for development of API intermediates manufacturing units are anticipated to offer remunerative opportunities for the expansion of the market during the forecast period.
The global API intermediates market is segmented into type, application, end user, and region. By type, the market is divided into bulk drug intermediates and chemical intermediates. On the basis of application, the market is divided into analgesics, anti-infective drugs, antidiabetic drugs, cardiovascular drugs, anticancer drugs and others. By end user, the market is segmented into biotech & pharmaceutical companies, CMO and research laboratories. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global API intermediates market Include Anyang General Chemical Co., Ltd., Sandoo Pharmaceuticals, Evonik Industries AG, Shree Ganesh Remedies Limited, Pfizer, Cambrex Corporation, Zeal & Innovation in Medicine, cation pharma, Hikal Ltd., and Espee.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the API intermediate market analysis from 2022 to 2032 to identify the prevailing API intermediate market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the API intermediate market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report Includes the analysis of the regional as well as global API intermediate market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Type
- Bulk Drug Intermediates
- Chemical Intermediates
By Application
- Analgesics
- Anti-Infective Drugs
- Antidiabetic Drugs
- Cardiovascular Drugs
- Anticancer Drugs
- Others
By End User
- Biotech and Pharmaceutical Companies
- CMO
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Anyang General Chemical Co., Ltd.
- Cambrex Corporation
- Cation Pharma
- Espee
- Evonik Industries AG.
- Hikal Ltd
- Pfizer Inc.
- Sandoo Pharmaceuticals
- Shree Ganesh Remedies Limited
- Zeal & Innovation in Medicine
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: API INTERMEDIATE MARKET, BY TYPE
CHAPTER 5: API INTERMEDIATE MARKET, BY APPLICATION
CHAPTER 6: API INTERMEDIATE MARKET, BY END USER
CHAPTER 7: API INTERMEDIATE MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to a new report, titled, 'API Intermediate Market,' The api intermediate market was valued at $139.4 billion in 2022, and is estimated to reach $285 billion by 2032, growing at a CAGR of 7.4% from 2023 to 2032.Active pharmaceutical ingredient (API) is a chemical or mixture of chemicals intended to be used in the manufacture of a drug. Such chemicals have pharmacological activities or other direct effects in the diagnosis, treatment, relief of symptoms, management, or prevention of diseases, or can affect the function and structure of the body. Intermediate is a substance that occurs during the API process and must undergo further molecular changes or refinement to become an API.
Key factors driving the growth of the API Intermediates market include rise in prevalence of chronic diseases, high presence of market players, and surge in number of geriatric populations. The biopharmaceutical business is rapidly growing owing to invention of numerous life-saving treatments that can cure cancer, tumors, and other chronic diseases with minimal side effects. As a result, people globally are rapidly adopting biotechnology medicinal products, particularly in industrialized regions such as North America and Europe. Furthermore, rise in usage of pharmaceutical intermediates across various research centers and institutes is expected to create numerous potential opportunities to market participants in the future.
Moreover, rise in expenditure by government for development of the pharmaceutical sector is expected to drive the growth of the market during the forecast period. For instance, in 2022, according to the Ministry of Chemicals and fertilizers of India, India was one of the major producers of active pharma ingredients (API) or bulk drugs in the world. India exported bulk drugs/drug intermediates worth $403.7 million in financial year 2021-22. However, the country also imports various bulk drugs/APIs for producing medicines from various countries. Thus, rise in revenue generation by developing countries such as India by exporting API intermediates boosts the growth of market. Moreover, high presence of market players who manufactures API intermediates and increase in usage of pain killer drugs by population is anticipated to boost the demand of drugs and expected to drive the growth of API intermediates market.
The global API intermediates market is segmented into type, application, end user, and region. By type, the market is divided into bulk drug intermediates and chemical intermediates. Based on application, the market is divided into analgesics, anti-infective drugs, antidiabetic drugs, cardiovascular drugs, anticancer drugs and others. By end user, the market is segmented into biotech & pharmaceutical companies, CMO and research laboratories. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
The key players profiled in the study include Anyang General Chemical Co., Ltd., Sandoo Pharmaceuticals, Evonik Industries AG, Shree Ganesh Remedies Limited, Pfizer, Cambrex Corporation, Zeal & Innovation in Medicine, cation pharma, Hikal Ltd., and Espee. The players in the market have been actively engaged in the adoption various strategies such as acquisition, product launch and expansion to remain competitive and gain advantage over the competitors in the market in November 2022, Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, announced that it has entered into a definitive agreement to acquire Snapdragon Chemistry, a leading US-based provider of chemical process development services which is specialized in active pharmaceutical ingredient (API) batch and continuous flow process development. The new facility expanded the company's capacity for supplying clinical intermediates and drug substances.
Moreover, in May 2022, Cambrex announced the completion of a $50 million expansion of its large-scale active pharmaceutical ingredient (API) manufacturing capabilities at its Charles City, Iowa facility. The facility is located on a 45-acre property and produces a wide range of APIs and pharmaceutical intermediates, including highly potent molecules and controlled substances.
Key Market Insights
- By type, bulk drug intermediates segment was the highest revenue contributor to the market and is estimated to reach $222,152.48 million by 2032, with a CAGR of 7.6%.
- By application, the $222,152.48 million by 2032 segment dominated the global market. However, the cardiovascular drugs segment is expected to be the fastest-growing segment with a CAGR of 9.0% during the forecast period.
- By end user, the biotech and pharmaceutical companies segment dominated the global market. However, the same segment is expected to be the fastest-growing segment with a CAGR of 7.7% during the forecast period.
- Based on region, Asia-Pacific garnered the largest revenue share in 2022, whereas North America is anticipated to grow at the highest CAGR of 8.0% during the forecast period
Companies Mentioned
- Anyang General Chemical Co., Ltd.
- Cambrex Corporation
- Cation Pharma
- Espee
- Evonik Industries AG.
- Hikal Ltd
- Pfizer Inc.
- Sandoo Pharmaceuticals
- Shree Ganesh Remedies Limited
- Zeal & Innovation in Medicine
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
